0001437749-21-012911.txt : 20210622 0001437749-21-012911.hdr.sgml : 20210622 20210520161450 ACCESSION NUMBER: 0001437749-21-012911 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20210520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NAVIDEA BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000810509 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 311080091 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147937500 MAIL ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: NEOPROBE CORP DATE OF NAME CHANGE: 19940714 CORRESP 1 filename1.htm navb20210520_corresp.htm
 
img01.jpg

May 20, 2021                                  

 

VIA EDGAR SUBMISSION

 

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

 

Re:

Navidea Biopharmaceuticals, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-256093) (as amended, the “Registration Statement”)

 

Dear Ladies and Gentlemen:

 

Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on Monday, May 24, 2021, at 6:00 a.m., Eastern Time, or as soon thereafter as is practicable.

 

If you have any questions regarding this request, please contact our outside counsel, Faith L. Charles of Thompson Hine LLP, at (212) 908-3905, or Kaoru Suzuki at (513) 352-6569. Please also call Faith L. Charles or Kaoru Suzuki as soon as the Company’s Registration Statement on Form S-1 has been declared effective. Thank you for your attention to this matter.

 

 

Sincerely,

 

NAVIDEA BIOPHARMACEUTICALS, INC.
   
   
  By: /s/ Jed A. Latkin                 
  Name:  Jed A. Latkin
  Title:

Chief Executive Officer, Chief Financial Officer and

Chief Operating Officer

 

 

cc:

Faith L. Charles, Thompson Hine LLP

 

Kaoru Suzuki, Thompson Hine LLP

 

 
 GRAPHIC 2 img01.jpg begin 644 img01.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0 L17AI9@ 34T *@ @ 0$Q ( M * &@ !''EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3% MQL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! M 0$! 0$ ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D: M)BH*# MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3 MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:3-87B MSQ;IW@[38[_5_-\F201+Y2;CN/M^%,\*>,=+\96,MWH\CE(I/+=9%VLIQZ57 M*[7Z$<\>;EOJ=!FC-9NNZU:^'M%N-4O]WV:V7=)L7)QGL*K>%?%>G>+]+;4- M(\WR%D,1\U-IW#KQ^-*SM-?%<7@WPZ M^JS6SW*)(D?EHP4G#?$T?B[PU#K$-NULDS,HC=@ M2,''45O9I6MH"::N@)I :R/$^N+X;\-WNKR0M.MI'O,:G!;\:H>!O&$?C70W MU&&T>T5)C$4D8,#W#C_XJO3HPPRC M[[NSY?&U\SE/]U'E1W6E_$+1]0VI/*;24_PS# _/I73PW$<\8>&174CJIR*\ M>/A/3?\ H:M+/_ Q_P#%5[ M7A?T9ZT#3NU(-(N !]^*4*Q^HSBM:+Q+HL\RQ0ZK9R2/PJ), M&)_ 5Q.+1[U.HIHUT_Z_4_D:X_Q'X9-_P#!'P]KMHI%SID'SLHY M,9;D_@<'\Z[Z;7LN5]3R:Z?UCF70]0^*AS\,=:_ZX_U%8'P(./ $Y/3[;)_( M55U'Q,/%/[/U[>LP-REN(;D9Z2*0#^8P?QH^#4$UU\+-1M[6013RSS)'(>BL M5 !_.LN6U)I]S;GYJZDNQ;\0_'#0]'U&2RL+6?4I(F*-)$0L>X=0">OX5GV/ MQ_TR2X5-3T:[M4)&9$8/M'KCK6C\/?AM!X+:[N=>N+"\N)=HAEVX$:CJ/F]3 M2?%E?#]YX#O3')8->P[7AV,N\'(Z8YZ&A1IM\J02G647-RL;_B/XAZ?X?\,V M>O1V\VH6%VX5)+VD\^-3U ;AA^##]:F M5)C>+O%=GX/T%]4OXWE0.L:QQXW.Q[#-<&"*W^Z.I%9-I>R6/[,KM =K2EHU5R0BG*6I*J5).,(Z75S'\1 M?%[1/%?@75]-,$]A>RP%8XYAD.<] 1_6MWX#G'@*X_Z_9/Y"KGQ8\+Z-/X(U M'4WT^%;VTBWQ3QJ%8'/J.HKF?AK?R:7\$M=O8N)(7G*X/0[1S^M5[KI6CW(O M.->\^QO^)?C9H>AZA+8V5O-JY)ZUVGQ(LO#^L>"-1 MV26+74$)E@>-TW*R\\8_*ER4U+DL-5*LH>TYOD=K8:I:ZEIT5_93++;2IO25 M3P17G6N?'30].OGM=,LY]29&*F6,A4)'H3UK.^$;7FM?"O5M)@G\F57DAADD MZ1[US^F36S\//AU!X(MKI]=N+*ZNY6&R8K@(@'0;O>HY(1;4M31U*M2,7#2Y MC6GQVT.\F$&MZ)/;QM]YB%D"CU*]:S/BA\/]'D\/CQ;X5BCCB($D\G)CX;V3:_P#! :;+( 9H MY[9&89"\D#\JT5H)3CH9-2G)TI:GSOL4XX6M+1O#.J^(;@1:-ILUT3_&J?(O MU;H*]X\-_!'P_I0275VDU:X7M+\L8_X".OXUZ-:V<%G L%I#'!$@PJ1J%4?@ M*WGC%]E'/2RZ3UFSQ/PY\ &DVR^)[\)W^S6?]7/]!7JN@^#- \,Q!-&TRWMV MQ\TNS+M]6/-;P&*,5P3J2GN>I3H0I_"AO2BG45F;GEWQ]_Y$>T_Z_4_D:W/A M]9Q7_P )=*M+A0\4]F8W4]P20:J_&'P]JGB3PK;6FBVQN9UNE=D#!<* >>?K M6YX!TV[TCP)I5CJ,/DW,$&V2/(.TY/R2\SCY&Z[;VL> R3S>"O^$K M\(W['R+F,B'(ZL""K?BO%=M\.-<;PW\$=8U:-!)):SR,BGH6(4#/XFM+XP> M+[Q%<66JZ!:^?>H/)GC5@I=.JGGT.?SJ?P+X%OO^%6ZGX=\0V[64E[*^!N#% M00,-Q[BNB52$J:ON(-?N4B,S1JJ')8CK@= M *T/&/P@T3PQX-O]6M[B\GNK= R-)(-N<@<@"J.D:9\3?AW-/9:1IXOK21]W M[M?,C8_WASE2>XJ[>^'_ (F>/[61=?9-.LHT+I;8">E%VI)WT% MRQ<&N5\QU/P+Y^'A'_3W)_2N/@!\!_M &,_)9ZBY"^FR7G]&%>@?"30]2\/^ M##9ZW:FUN3<.Y0L&X.,'(K(^,/@G4?$L6GW^A6WGWMLQC=%8*2AYSD^A_G6: MG%U9)[,VE3E["+6Z.7\)QGQS\=KW6)/FM+!VD3([+\D8_F:[GXU_\DRNO^NT M7_H5,^$'@^\\+>'[F35[?R+^[F+.A8$J@X )'XG\:T?BEHU_K_@2XL-(M_M% MRTL96,,!P&SU-*4TZJMLBXTY*A*^[//-C/\ LPC:,[9=Q^@EKL_@G-&_PUMH MT;)CFD5QZ'=G^M/\'^$;@_"0>'/$$+6TDR2)*@8$IN8D'(_"O/=,T?XD_#F[ MN;71+ W]I(^[Y%$D;_[6,Y4D=:IM3C*-^IG%2I2C.VEK'JGQ2/\ Q;/6Q_T[ M_P!17G7@>-IO@!XB1 6),V ._ I+OP_\3?'T#QZ^ZZ;8JI86Y^3S2.BE1R>? M7BNO^%7AG4='\"W6F^(K/R)+B>0M$S!LHPQVJ=(4[7ZCM*K5YK:6/,_AM\-M M.\-WV?&/^^C6DY3D[QEH9 MTXTXQY9Q=SH9='C^$/P\U>YTNZDNY78/&TX VN?E' Z@5Q/@_P"'VH?$?3GU MSQ!X@N@DDK(BJ=Q..IYX ]A7HT'A_7/$_P +YM(\8R+'JET&W.-IV'=E#\O' M'%>=Z-:?%#X?^9IVF:7]MM"Y90B>;&3W9<$$9]#4P=T]?>*J12E'1\I/XY^$ MNA^%/!=WJEI<7D]W"4VF608Y8 \ 5VOP58)\,;7/3SI?_0JXO4O#'Q+\>6>&,[BNX_(S!>JC MG(%$G>GRMZA3]VJYQC96/8$8,>*?7*^!;6]M-'D6]69(C)F!)N& P-QQU +9 M(!Z"NHS7(U9GI1=U<=12 YI:10E%%% PSUYI /:G44 -VYZT;:=10 W;28S MU%/HH :%J&YE%O;R2MT12QS[58JM?V@OK&:V9F19D*%EZ@&FMR9WY78XRW\6 M:@\!E\R";-N9=JQ%/+8D!!R>>3BKC:_J/FI< 0?9/M*VS(5.]ST9@>W/\JN+ MX1B*?Z3=W$[*J(K-@;55@V .Y S3U\*0BX9VN9VCWM)'"6^6-V!RP_,UOS0 M/,5/$]S%A\67K1&X$EM.FR5VC2-@8@N=I+9P988+H70AP0650<$''?Y342>+;N&.U:3RIX9KOR_/5 M"H:+'+ 'I@\5LP^%;.VNO-MP8T$PF$2CY=P7;_6D7PG9D;)R\T($BB-^@5SD MC\*=Z9'L\5NF4HO%,DR:G+'"IBMY%AM<\&5R.OTR:='KFH7UO8V]GY,=Y/&T MDS."53:<' [Y/%6AX1L6F#3!I(Q(9!"P^7)4+T]@.*C_ .$/MX]GV2[N+8IN M&8B,E&.2O3@>_6B\"E#$]2F=26-O(HCWW%Z84P#C8&()Z]>#5J'PV;?4)+B#4+A$D96>(A6#8&,$D9[4MCX M7ALKI)?M$TR0LS00OC;$6ZXXSGFDW$<:=?J98UC5XH[R62>WE6&X%O&!$1N8 MX]^V?TJ[9:EJEU(+W%LNG;W!4Y#A 2 ^?PZ5<7P_"+=(3)(0MS]I)/\ $V$8PCPF^NC;'(6'< J*3D@<<^F3VHO%A[.M%Z%2/Q/<2:?J4_EHC1;6M MA_>5N%)]R:OZ_JESIMI;M%MC,K[9)V0NL7&V,?K0^2XU'$*+3W-+2IY+C3X99I8I6 M= Q>'[K>XJ[56QLH["RBMH 1'$H50?2K59/<[HW45<2BBBD4+1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__ !V0$! end